Can reimbursement unlock the next wave of office-based cancer care? What ZUSDURI and CMS J-codes reveal about oncology’s outpatient shift

UroGen Pharma Ltd. (NASDAQ: URGN) is positioning itself at the forefront of a potential transformation in how certain cancers are treated in the United States. With its recently approved bladder cancer therapy ZUSDURI, the company is not just launching a drug but aligning its commercial strategy with a broader shift in healthcare delivery: moving cancer care out of hospitals and into office-based settings. Central to this approach is the assignment of a permanent J-code—specifically J9282—by the Centers for Medicare & Medicaid Services, which takes effect on January 1, 2026.

This code, designed for non-oral, physician-administered oncology drugs, creates a standardized billing pathway. It is being seen as a key inflection point, not only for ZUSDURI’s uptake but for how the broader oncology ecosystem might evolve. The move signals the growing influence of reimbursement infrastructure in determining how and where patients receive cancer treatment.

Traditionally, oncology care in the United States has largely concentrated in hospital outpatient departments or inpatient units. These settings offered the billing clarity and administrative ease that physician practices often lacked. As a result, physician offices faced barriers to entry despite offering potentially lower costs and better access for many patients. In the case of bladder cancer, where recurring surgical interventions are common, the opportunity to administer therapy in a urology clinic or office-based setting holds strong appeal, both clinically and economically.

ZUSDURI, approved in June 2025 by the United States Food and Drug Administration, is indicated for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. This subgroup of patients often suffers repeated tumor recurrence but is not always eligible for radical surgical solutions like cystectomy. Until now, treatment for such patients typically involved repeated transurethral resections under anesthesia, which is a burdensome and costly process for both patient and system.

UroGen Pharma’s approach with ZUSDURI leverages its proprietary RTGel technology, a hydrogel formulation that sustains drug exposure within the bladder. Administered via catheter, the therapy can be delivered in a community urology office, avoiding hospital settings altogether. However, before the J-code designation, uptake was limited due to complex and manual billing processes. Without a permanent billing code, providers often had to navigate temporary or miscellaneous reimbursement mechanisms, which deterred many practices from integrating the therapy into routine care.

How does the new J-code for ZUSDURI unlock the next phase of outpatient oncology care delivery?

The permanent assignment of J9282 eliminates much of this administrative friction. For UroGen Pharma, this is more than a billing milestone—it is a commercial unlock. The company now anticipates significantly accelerated adoption of ZUSDURI beginning in 2026. It has publicly stated a peak revenue ambition of $1 billion for the therapy, a target that hinges on streamlined reimbursement workflows and wide-scale physician-office integration.

The broader shift toward office-based oncology treatment is not new but has been gaining momentum in recent years. Between 2008 and 2016, the proportion of Medicare Part B oncology drug claims handled in hospital outpatient departments nearly doubled, largely driven by reimbursement structures that favored those settings. In contrast, independent physician practices have often struggled to justify adopting new therapies that lack clear reimbursement frameworks. By assigning a permanent J-code to ZUSDURI, the Centers for Medicare & Medicaid Services may be signaling a rebalancing of the playing field.

Why is oncology care shifting from hospitals to physician offices—and where does ZUSDURI fit in?

UroGen Pharma’s latest financial disclosures reflect the early-stage nature of the ZUSDURI rollout. In the third quarter of fiscal year 2025, ZUSDURI generated approximately $1.8 million in revenue. October 2025 figures showed a preliminary surge to $4.5 million, indicating growing momentum. More than 590 sites of care had been activated since the July launch, with 54 unique prescribers and 16 repeat prescribers. These metrics, while still modest, point to positive movement ahead of the 2026 billing transformation.

The company’s flagship product, JELMYTO, continues to underpin total revenues. For the third quarter of 2025, UroGen Pharma reported $25.7 million in JELMYTO sales, up 13 percent year-over-year. The company ended the quarter with a cash position of $127.4 million, offering it some runway to execute on its ZUSDURI strategy.

What do early sales of ZUSDURI reveal about physician uptake and investor expectations before 2026?

While investors remain cautiously optimistic, many are waiting for additional signs of commercial traction before turning more bullish. The permanent J-code reduces reimbursement risk, but execution risk remains significant. Analysts are focusing on indicators such as the pace of site activation, payer policy adoption, and the frequency of patient re-treatment cycles to assess whether UroGen Pharma can meet its peak revenue goals.

Importantly, reimbursement clarity is necessary but not sufficient to guarantee adoption. Office-based settings require logistical readiness, staff training, inventory planning, and payer-specific policy understanding to implement new therapies smoothly. Even with a permanent billing code in place, practices must still secure favorable formulary positions, gain prior authorization from commercial insurers, and ensure reimbursement rates justify the investment.

What are the remaining hurdles to office-based oncology—and can reimbursement reforms truly overcome them?

Payer behavior remains a variable. While physician-office administration may be lower cost than hospital outpatient delivery, payers do not always incentivize this shift consistently. Reimbursement differentials, bundling practices, and prior authorization hurdles can still influence provider decision-making. That said, the trend in healthcare has increasingly leaned toward value-based models, and therapies like ZUSDURI, which reduce surgical interventions and support in-office administration, align well with this direction.

From a strategic perspective, UroGen Pharma is executing a playbook that many in the biotech industry are beginning to emulate. The idea of designing a therapy not just around its molecular efficacy but also around its delivery and reimbursement model is gaining traction. Commercial success increasingly depends on whether a product fits within evolving care pathways and infrastructure, and not just clinical guidelines.

Can reimbursement-first strategies reshape oncology launches—and will more cancer drugs follow ZUSDURI’s path?

ZUSDURI represents an early and highly visible example of this. Its design, delivery route, and reimbursement strategy are all optimized for outpatient integration. If successful, UroGen Pharma may set a precedent for other companies looking to introduce therapies into community settings. The RTGel platform, in particular, could be leveraged for other localized cancers, expanding the company’s footprint and potential licensing opportunities.

Beyond the business case, there are strong implications for healthcare policy and patient access. Decentralizing oncology care by enabling office-based treatment helps reduce system-wide costs, alleviate hospital burden, and improve patient convenience. For bladder cancer specifically, where recurrence is high and treatment typically invasive, the prospect of effective in-office chemoablation could meaningfully change the standard of care.

What should analysts, prescribers, and payers watch as UroGen Pharma pushes ZUSDURI toward scale in 2026?

As the 2026 reimbursement update approaches, all eyes are on whether UroGen Pharma can translate this infrastructure improvement into tangible adoption gains. Physicians, payers, and investors are aligned in watching three core metrics: how quickly and broadly sites of care come online, how commercial insurers respond to the J-code in their policies, and how frequently prescribers re-use ZUSDURI in the same patient population.

The commercial model also opens interesting questions about scalability. If ZUSDURI performs well and captures a significant portion of the intermediate-risk bladder cancer market, UroGen Pharma could evolve into a commercial-stage leader in urologic oncology. Conversely, if adoption remains limited to academic centers and fails to penetrate the community urology network, the therapy risks being a niche success rather than a market-defining product.

In either case, the strategic use of a J-code to support a decentralized cancer care model is now part of the playbook for future oncology launches. Biotech and pharma companies that fail to account for site-of-care dynamics in their commercialization planning may find themselves at a disadvantage in this new era of value-based, infrastructure-sensitive healthcare delivery.

The ZUSDURI story is ultimately not just about one drug. It is a lens into how regulatory and payer-side developments, such as permanent billing codes, are shaping the future of cancer treatment. For UroGen Pharma, the stakes are clear. The infrastructure is now in place. The question is whether execution can match ambition.

Key takeaways: What should investors, clinicians, and market watchers keep in focus?

UroGen Pharma has built a commercialization strategy around ZUSDURI that places outpatient oncology at the center of care. With the assignment of J9282 as a permanent reimbursement code, billing friction is expected to ease significantly from January 2026, potentially unlocking broader physician adoption. This shift aligns with larger healthcare trends favoring decentralization and value-based models. Although early sales remain modest, the market is watching for indicators such as payer policy clarity, prescriber uptake, and repeat cycles. The next 12 to 18 months will define whether ZUSDURI becomes a $1 billion franchise or remains a proof-of-concept. Either way, the role of reimbursement codes in shaping site-of-care economics is now more important than ever in oncology.